Zykadia 150 mg hard capsules

DRUG2 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Institut National De La Sante Et De La Recherche Medicale

Conditions

ALK+ NSCLCUnresectable locally advanced and/or metastatic soft-tissue sarcomalocally advanced (stage III) and not suitable for curative treatmentor metastatic (stage IV) ALK+ NSCLC

Phase 2

ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Active, not recruitingCTIS2024-513947-94-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHALK+ NSCLC, locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC

Start: 2020-03-30Target: 118Updated: 2025-12-17

Phase 3

MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study

RecruitingCTIS2024-514873-22-00

Institut National De La Sante Et De La Recherche MedicaleUnresectable locally advanced and/or metastatic soft-tissue sarcoma

Start: 2019-10-16Target: 960Updated: 2025-11-26